Physician profile
Grant Pickett
NPI 1225526874
$6,849.54
in general payments reported to CMS, 2019-2025
27 companies · $1,649 in 2025
The $1,649 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2021: $329 · 2022: $939 · 2023: $835 · 2024: $2,833 · 2025: $1,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,284 · Consulting Fee: $16.95 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,283.92 |
| Consulting Fee | $16.95 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,801.61 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $512.86 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $509.01 | 2022-2025 | Cuvitru, Takhzyro, Eohilia |
| Grifols USA, LLC | $470.30 | 2021-2025 | Xembify |
| Regeneron Healthcare Solutions, INC. | $443.13 | 2022-2025 | Dupixent |
| Genzyme Corporation | $391.26 | 2022-2025 | |
| Adma Biomanufacturing LLC | $347.91 | 2022-2025 | |
| Csl Behring | $293.48 | 2023-2025 | Haegarda, Hizentra |
| Incyte Corporation | $242.86 | 2022-2024 | Opzelura |
| Pfizer INC. | $234.98 | 2019-2023 | |
| Ars Pharmaceuticals Operations, INC. | $212.45 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $195.72 | 2024-2025 | |
| Kaleo, INC. | $152.58 | 2023-2024 | Auvi-Q |
| Abbott Laboratories | $147.32 | 2024 | Aveir |
| Abiomed | $129.66 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $122.06 | 2023-2025 | Ayvakit |
| Galderma Laboratories, L.P. | $115.94 | 2025 | Nemluvio |
| Amgen INC. | $113.43 | 2023-2025 | Tezspire |
| Pharming Healthcare, INC. | $104.38 | 2024-2025 | Ruconest |
| Optinose US, INC. | $73.01 | 2023-2024 | |
| Olympus America INC. | $50.33 | 2024 | Olympus |
| Alk-Abello, INC | $50.00 | 2023 | Grastek, Ragwitek, Odactra |
| Biocryst US Sales Co., LLC | $43.61 | 2023-2024 | Orladeyo |
| Cycle Pharmaceuticals INC | $26.44 | 2024-2025 | Sajazir |
| Hospira, INC. | $23.05 | 2025 | |
| Octapharma USA, INC. | $22.00 | 2023 | Cutaquig |
| Hikma Pharmaceuticals USA | $20.16 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Pickett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.